XORTX Therapeutics Statistics
Total Valuation
XRTX has a market cap or net worth of $2.98 million. The enterprise value is $1.82 million.
Important Dates
The next estimated earnings date is Friday, March 20, 2026, before market open.
| Earnings Date | Mar 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
XRTX has 6.96 million shares outstanding. The number of shares has increased by 53.07% in one year.
| Current Share Class | 6.96M |
| Shares Outstanding | 6.96M |
| Shares Change (YoY) | +53.07% |
| Shares Change (QoQ) | +28.20% |
| Owned by Insiders (%) | 2.00% |
| Owned by Institutions (%) | 4.29% |
| Float | 6.25M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.51 |
| P/TBV Ratio | 1.68 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.62, with a Debt / Equity ratio of 0.03.
| Current Ratio | 1.62 |
| Quick Ratio | 1.45 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -94.63% and return on invested capital (ROIC) is -71.41%.
| Return on Equity (ROE) | -94.63% |
| Return on Assets (ROA) | -45.32% |
| Return on Invested Capital (ROIC) | -71.41% |
| Return on Capital Employed (ROCE) | -122.37% |
| Weighted Average Cost of Capital (WACC) | 4.98% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$647,769 |
| Employee Count | 3 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -52.80% in the last 52 weeks. The beta is 0.15, so XRTX's price volatility has been lower than the market average.
| Beta (5Y) | 0.15 |
| 52-Week Price Change | -52.80% |
| 50-Day Moving Average | 0.57 |
| 200-Day Moving Average | 0.77 |
| Relative Strength Index (RSI) | 30.36 |
| Average Volume (20 Days) | 195,879 |
Short Selling Information
The latest short interest is 64,366, so 0.92% of the outstanding shares have been sold short.
| Short Interest | 64,366 |
| Short Previous Month | 58,074 |
| Short % of Shares Out | 0.92% |
| Short % of Float | 1.03% |
| Short Ratio (days to cover) | 1.40 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -2.42M |
| Pretax Income | -1.94M |
| Net Income | -1.94M |
| EBITDA | -2.44M |
| EBIT | -2.42M |
| Earnings Per Share (EPS) | -$0.50 |
Full Income StatementBalance Sheet
The company has $1.19 million in cash and $59,094 in debt, with a net cash position of $1.13 million or $0.16 per share.
| Cash & Cash Equivalents | 1.19M |
| Total Debt | 59,094 |
| Net Cash | 1.13M |
| Net Cash Per Share | $0.16 |
| Equity (Book Value) | 1.97M |
| Book Value Per Share | 0.38 |
| Working Capital | 520,071 |
Full Balance SheetCash Flow
| Operating Cash Flow | -2.95M |
| Capital Expenditures | n/a |
| Free Cash Flow | -2.95M |
| FCF Per Share | -$0.42 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
